



NCT

NATIONAL CENTER
FOR TUMOR DISEASES
PARTNER SITE DRESDEN
UNIVERSITY CANCER CENTER UCC

Supported by:
German Cancer Research Center
University Hospital Carl Gustav Carus Dresden
Carl Gustav Carus Faculty of Medicine, TU Dresden
Helmholtz-Zentrum Dresden-Rossendorf

Core Unit for Molecular Tumor Diagnostics

Input Recommendation for selected Protocol

Protocol	Illumina TruSight Tumor 170
Input Material	RNA
Minimum Input	40,0 ng
Standard Input	120,0 ng
Maximum Volume	8,5 µL
Minimal Concentration	4,71 ng/µL
Standard Concentration	14,12 ng/µL

Extraction derived from **FFPE/Non-FFPE**

RNA Qualityparameters

RIN	not considered
DV200	>30 %

For more Information please visit the manufacturers homepage

<https://emea.illumina.com/products/by-type/clinical-research-products/trusight-tumor-170.html>

https://emea.support.illumina.com/sequencing/sequencing_kits/trusight-tumor-170-kit.html

The CMTD is not responsible for the consequences/results, if an ordering work group wants to sequence RNA/DNA samples that failed the predefined quality parameters for sequencing!

Possible, risks which can occur are for example bad sequencing quality, no sequencing possible due to failure in library generation, introducing false signals of gene expression or allele frequency.

Erstellt: Alexander Krüger	Geändert: Alexander Krüger	Geprüft: Sandra Oster	Freigegeben:
Datum: 28.09.2021	Datum: 25.02.2022	Datum:	Datum: